1Weiderpass E, Labreche F. Malignant tumors of the female repro- ductive system[J]. Saf Health Work, 2012,3 (3) : 166-180.
2Colombo N, Carinelli S, Colombo A, et al. Cervical cancer:ESMO Clinical Practice Guidelines for diagnosis ,treatment and follow- up[J]. Ann Oncol,2012,23 Suppl 7 : vii27-32.
3Kato H, Torigoe T. Radioimmunoassay for tumor antigen of hu- man cervical squamous cell carcinoma[J]. Cancer, 1977,40 (4): 1621-1628.
4Silverman GA,Bartuski AJ,Cataltepe S,et al. SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3[J]. Tumour BM, 1998,19(6) :480-487.
5Crombach G, Wurz H, Herrmann F, et al. The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)[J]. Dtsch Med Wochenschr, 1989,114(18) :700-705.
6Kato H. Expression and function of squamous cell carcinoma an- tigen[J]. Anticancer Res, 1996,16(4B) :2149-2153.
7Suminami Y, Nawata S, Kato H. Biological role of SCC antigen[J]. Tumour Biol, 1998,19(6) :488-493.
8Uemura Y, Pak SC, Luke C, et al. Circulating serpin tumor mar- kers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells [J]. Int J Cancer, 2000, 89(4) : 368-377.
9Gaddueci A ,Tana R, Cosio S, et al. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer : a review of the litera- ture[J]. Crit Rev Oncol Hematol, 2008,66 ( 1 ) : 10-20.
10Chmura A, Wojeieszek A, Mrochem J, et al. Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and moni- toting of cervical squamous cell carcinoma[J]. Ginekol Pol, 2009, 80(5) :361-366.
